Synthetic vincamine derivative / cerebrovascular agent

Plain-language summaryIntrigue 50 / 100

Vinpocetine (Cavinton) is a synthetic alkaloid derived from vincamine in the lesser periwinkle plant, developed at Gedeon Richter in Hungary in the 1960s. Approved across Europe for cerebrovascular insufficiency and used as a nootropic in the US (sold as a supplement). It works through several mechanisms at once: cerebral vasodilation, weak phosphodiesterase 1 inhibition, neuronal sodium channel block, and modest antioxidant activity, with the combined effect of improving blood flow to the brain. Clinical evidence in cognitive impairment and stroke recovery is mixed and dominated by older Eastern European trials with weak methodology. The FDA flagged it in 2019 over concerns about miscarriage in pregnant users. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

32/100

A 1960s cerebrovascular workhorse with weak PDE1 inhibition that has been surpassed by more selective modern tools

Vinpocetine is one of those compounds that was genuinely interesting in 1975 and has been coasting on that reputation ever since. Developed at Gedeon Richter in Hungary as a synthetic derivative of vincamine, it got approval across Eastern Europe under the Cavinton trade name and built up a moderately sized clinical literature, mostly through the 1980s and 1990s. That history is real. The problem is that the research has barely moved since.

The mechanism is pluripotent in the way that usually signals we don’t really know what’s driving the effect. PDE1 inhibition is the most cited angle, and it’s not a bad one; PDE1B and PDE1C have legitimate neurological relevance, and the cyclic nucleotide signaling cascade downstream is genuinely interesting biology. But vinpocetine’s PDE1 affinity is weak relative to selective inhibitors that came later. The cerebrovascular vasodilation story is real but not mechanistically novel. The sodium channel block exists but is modest. What you end up with is a compound that does several things modestly well rather than one thing exceptionally.

Differentiation is where vinpocetine struggles most against modern alternatives. If you’re interested in PDE1 specifically, ITI-214 (now lenrispodun) is a selective, high-affinity PDE1 inhibitor with clean human pharmacology data and a phase 2 trial in heart failure. If you want cerebrovascular effects, the field has largely moved to better-characterized agents. Vinpocetine competes with neither, and its FDA story is awkward: the agency has questioned whether it legally qualifies as a dietary supplement given its pharmaceutical development history, which creates a real sourcing ambiguity for US-based research programs.

The evidence base is an honest moderate score. There’s a multi-decade literature, some small RCTs in European populations, and a Cochrane review that found evidence insufficient to support use in dementia. Not nothing. But a lot of the primary literature comes from Eastern European groups with methodological standards that dont hold up well against modern expectations, and independent replication from Western labs is sparse. The translational signal exists, it’s just not compelling by current standards.

We think vinpocetine still has marginal utility as a rough PDE1 inhibitor tool in preclinical CNS work, particularly when selectivity isn’t the priority and broad cerebrovascular modulation is the goal. Thats a narrow use case. For investigators seriously studying PDE1 biology, ITI-214 is the right probe. For cerebrovascular research, the compound landscape looks very different in 2025 than it did when Cavinton was approved. Vinpocetine is a historical artifact that still holds a slot in the library, but serious bench scientists should know what they’re not getting when they reach for it.

Novelty: 20
Mechanism promise: 32
In-category differentiation: 28
Evidence quality: 45
Translational signal: 40
Research bench value: 35

Rationale Developed in the 1960s with a multi-decade Eastern European clinical literature, vinpocetine’s pluripotent-but-weak mechanism and poor differentiation against selective modern PDE1 inhibitors keep novelty and differentiation scores low; evidence quality is moderate given the Cochrane-reviewed RCT base, but independent Western replication is sparse and effect sizes are modest throughout.

Synthetic vincamine derivative / cerebrovascular agent

A synthetic alkaloid derivative of vincamine from Vinca minor; a cerebrovascular agent and PDE1 inhibitor used as a nootropic.

Abstract

Vinpocetine ((3-alpha,16-alpha)-eburnamenine-14-carboxylic acid ethyl ester; CAS 42971-09-5; molecular formula C22H26N2O2; molecular weight 350.46) is a synthetic alkaloid derivative of vincamine from Vinca minor (lesser periwinkle), developed at Gedeon Richter (Hungary) in the 1960s and approved in many European countries as Cavinton for cerebrovascular insufficiency. Mechanism is multifactorial: cerebral vasodilation through smooth muscle relaxation, weak phosphodiesterase 1 (PDE1) inhibition, sodium channel block in neurons, and modest antioxidant activity. The combined effect produces improved cerebral blood flow and reduced ischemic neuronal injury in animal stroke models. Plasma half-life is approximately 1 to 2 hours; metabolism is hepatic via CYP2C9 and CYP3A4. Approved indications in Europe include cerebrovascular disorders, age-related cognitive decline, and tinnitus. In the US, the compound is sold as a dietary supplement with FDA reservations about that designation given its drug-like history. Used as a cerebrovascular nootropic and PDE1 inhibitor in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-305Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Synthetic vincamine derivative / cerebrovascular agent

Vinpocetine

Abstract

Read the full monograph